ClinicalTrials.gg
CompletedNCT02842853Updated Apr 5, 2022Results posted

Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine

A Phase 3 interventional study of Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine and Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Meningitis, Meningococcal Meningitis and Meningococcal Infections, sponsored by Sanofi Pasteur, a Sanofi Company. Completed at 89 sites in United States. Open to participants aged 10 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-05.

Primary conditionMeningitis, MeningococcalRegistry: MeningitisReclassifiedWhy we changed it
Registry
Meningitis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Meningitis, Meningococcal
Why
  1. The study's listed conditions name Meningitis, Meningococcal, a narrower term within Meningitis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 3, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,344
Allocation
Randomized
Ages
10 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Meningitis, Meningococcal by Sanofi — none open to participants now, none under way, none of them phase 3. Meningitis, Meningococcal · Sanofi.

Enrollment
Largest of 23
3,344 · median 907
Started
2016
with 6 others
Phase 3
13 of 24
none open now
Registered
15th of 24
by date

Among the 24 studies in Meningitis, Meningococcal by Sanofi, this one has the largest enrollment of the 23 interventional ones that give a count, is one of 7 that started in 2016, is one of 13 in phase 3, and was the 15th registered.

Meningitis, Meningococcal

125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.

Browse Meningitis, Meningococcal studies →

Open to participants now

None of the 24 studies in Meningitis, Meningococcal by Sanofi is open now. The open studies under Meningitis, Meningococcal, anywhere →

Who these studies take

Of the 5 Meningitis, Meningococcal studies recruiting now, none set no upper age limit and 5 stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 10 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 24 studies in Meningitis, Meningococcal by Sanofi as a file.
02

Study summary

The purpose of the study was to evaluate immune lot consistency of Meningococcal Polysaccharide (Serogroups A, C, Y and W) Tetanus Toxoid (MenACYW) Conjugate vaccine and the immune non-inferiority compared to the licensed vaccine Menactra®, and describe the safety and additional immunogenicity of these study vaccines in adolescents and adults 10 to 55 years of age in the United States (US).

Primary Objectives:

  • To demonstrate the immune lot consistency of the antibody responses to meningococcal serogroups A, C, Y, and W following the administration of a single dose of MenACYW Conjugate vaccine with respect to serum bactericidal assay using human complement (hSBA) geometric mean titers (GMTs).
  • To demonstrate the non-inferiority of the antibody responses to meningococcal serogroups A, C, Y, and W following the administration of a single dose of MenACYW Conjugate vaccine (pooled Lots 1 to 3) compared to those observed following the administration of a single dose of Menactra®.

Secondary Objective:

  • To demonstrate the non-inferiority of the antibody responses to meningococcal serogroups A, C, Y, and W following the administration of a single dose of MenACYW Conjugate vaccine (pooled Lots 1 to 3) compared to those observed following the administration of a single dose of Menactra® in the adult population (18 to 55 years old).
  • To demonstrate the non-inferiority of the antibody responses to meningococcal serogroups A, C, Y, and W following the administration of a single dose of MenACYW Conjugate vaccine (pooled Lots 1 to 3) compared to those observed following the administration of a single dose of Menactra® in the adolescent population (10 to 17 years old).
  • To compare the hSBA vaccine seroresponses of meningococcal serogroups A, C, Y, and W for each of 3 lots of MenACYW Conjugate vaccine 30 days (+14 days) after vaccination.
  • To compare the hSBA antibody GMTs of meningococcal serogroups A, C, Y, and W following the administration of MenACYW Conjugate vaccine to those observed following the administration of Menactra®.

Observational Objectives:

  • To describe the safety profile of MenACYW Conjugate vaccine and that of the licensed Menactra®.
Read the detailed description

Healthy meningococcal-vaccine naïve adolescents and adults were randomized and received a single dose of either MenACYW Conjugate vaccine from 1 of the 3 lots (Lot 1, Lot 2, or Lot 3) or Menactra®. They were assessed for immunogenicity at baseline (pre-vaccination) and at 30 to 44 days post-vaccination. Safety information were collected post-vaccination and throughout the entire study.

03

Conditions studied

  • Meningitis
  • Meningococcal Meningitis
  • Meningococcal Infections

Browse trials for

Keywords

  • Meningitis
  • Meningococcal Meningitis
  • Meningococcal Infections
  • MenACYW Conjugate vaccine
  • Licensed MCV4 vaccine
04

In context

Meningitis, Meningococcal Reclassified

125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.

This study's enrollment of 3,344 is above the median of 538 across 113 interventional studies indexed under Meningitis, Meningococcal.

Browse Meningitis, Meningococcal studies →

Lead sponsor

Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.

Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.

First submitted after Sanofi Pasteur became part of Sanofi.

Compared within Meningitis, Meningococcal, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Meningitis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
10 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 10 to 55 years on the day of inclusion.
  • form was signed and dated by the participant (aged 18 to 55 years) or assent form was signed and dated by the participant and informed consent form was signed and dated by the parent(s) or guardian (for participants aged 10 to \< 18 years).
  • Participant (>= 18 years) or participant (10 to \< 18 years) and parent / guardian were able to attend all scheduled visits and comply with all trial procedures.

Exclusion criteria

Exclusion Criteria:

  • Participant was pregnant, or lactating, or of (to be considered of non-childbearing potential, a female must have been pre-menarche or for at least 1 year, surgically sterile, or using an effective method of or abstinence from at least 4 weeks prior to vaccination until at least 4 weeks after vaccination).
  • Participation in the 4 weeks preceding the trial vaccination or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure.
  • Receipt of any vaccine in the 4 weeks (28 days) preceding the trial vaccination or planned receipt of any vaccine prior to Visit 2 except for influenza vaccination, which may be received at least 2 weeks before or after the study vaccines. This exception includes monovalent pandemic influenza vaccines and multivalent influenza vaccines.
  • Previous vaccination against meningococcal disease with either the trial vaccine or another vaccine (i.e., mono- or polyvalent, polysaccharide, or conjugate meningococcal vaccine containing serogroups A, C, Y, or W; or meningococcal B vaccine).
  • Receipt of immune globulins, blood or blood-derived products in the past 3 months.
  • Known or suspected congenital or acquired immunodeficiency; or receipt of therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).
  • History of meningococcal infection, confirmed either clinically, serologically, or microbiologically.
  • At high risk for meningococcal infection during the trial (specifically, but not limited to, participants with persistent complement deficiency, with anatomic or functional asplenia, or participants traveling to countries with high endemic or epidemic disease).
  • Known systemic to any of the vaccine components, or history of a life-threatening reaction to the vaccines used in the trial or to a vaccine containing any of the same substances.
  • Verbal report of thrombocytopenia, as reported by the participant or the participant's parent / guardian, contraindicating intramuscular vaccination in the Investigator's opinion.
  • Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination in the Investigator's opinion.
  • Personal history of Guillain-Barre syndrome.
  • Personal history of an Arthus-like reaction after vaccination with a tetanus toxoid-containing vaccine within 10 years of the proposed study vaccination.
  • Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily.
  • Current alcohol abuse or drug addiction.
  • Chronic illness that, in the opinion of the Investigator, was at a stage where it might interfere with trial conduct or completion.
  • Moderate or severe acute illness/infection (according to Investigator judgment) on the day of vaccination or febrile illness (temperature >= 100.4 degree Fahrenheit [°F]). A prospective participant was not be included in the study until the condition was resolved or the febrile event had subsided.
  • Receipt of oral or injectable antibiotic therapy within 72 hours prior to the first blood draw.
  • Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (i.e., parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
3,344 participants (actual)

Study arms

  • Experimental
    MenACYW Conjugate Vaccine Lot 1

    Healthy, meningococcal-vaccine naive adolescents aged 10 to 17 years (Group 1a) and adults aged 18 to 55 years (Group 1b) received a single dose of MenACYW conjugate vaccine from lot 1 on Day 0.

    Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine

  • Experimental
    MenACYW Conjugate Vaccine Lot 2

    Healthy, meningococcal-vaccine naive adolescents aged 10 to 17 years (Group 2a) and adults aged 18 to 55 years (Group 2b) received a single dose of MenACYW conjugate vaccine from lot 2 on Day 0.

    Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine

  • Experimental
    MenACYW Conjugate Vaccine Lot 3

    Healthy, meningococcal-vaccine naive adolescents aged 10 to 17 years (Group 3a) and adults aged 18 to 55 years (Group 3b) received a single dose of MenACYW conjugate vaccine from lot 3 on Day 0.

    Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine

  • Active comparator
    Menactra®

    Healthy, meningococcal-vaccine naive adolescents aged 10 to 17 years (Group 4a) and adults aged 18 to 55 years (Group 4b) received a single dose of Menactra® on Day 0.

    Biological: Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine

Interventions

  • BiologicalMeningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine

    0.5 mL, Intramuscular

    Also known as: MenACYW conjugate vaccine

  • BiologicalMeningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine

    0.5 mL, Intramuscular

    Also known as: Menactra®

07

What researchers measure

Primary outcomes

  1. Geometric Mean Titers (GMTs) of Meningococcal Serogroups A, C, Y, And W Antibodies Following Vaccination With 3 Lots of MenACYW Conjugate Vaccine

    Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by serum bactericidal assay using human complement (hSBA). Data for this outcome measure were not planned to be collected and analyzed for the Menactra® reporting group.

    Time frame: Day 30 (post-vaccination)

  2. Percentage of Participants Achieving hSBA Vaccine Seroresponse for Meningococcal Serogroups A, C, Y And W Following Vaccination With Either MenACYW Conjugate Vaccine or Menactra® Vaccine

    Antibody titers against meningococcal serogroups A, C, Y, and W measured by hSBA. The hSBA vaccine seroresponse for serogroups A, C, Y, and W was defined as post-vaccination hSBA titers \>= 1:16 for participants with pre-vaccination hSBA titers \< 1:8 or at least a 4-fold increase in hSBA titers from pre- to post-vaccination for participants with pre-vaccination hSBA titers \>= 1:8.

    Time frame: Day 30 (post-vaccination)

Secondary outcomes

  1. Percentage of Participants Achieving hSBA Vaccine Seroresponse for Meningococcal Serogroups A, C, Y And W Following Vaccination With Either MenACYW Conjugate Vaccine or Menactra® Vaccine in Adults

    Antibody titers against meningococcal serogroups A, C, Y, and W measured by hSBA. The hSBA vaccine seroresponse for serogroups A, C, Y, and W was defined as post-vaccination hSBA titers \>= 1:16 for participants with pre-vaccination hSBA titers \< 1:8 or at least a 4-fold increase in hSBA titers from pre- to post-vaccination for participants with pre-vaccination hSBA titers \>= 1:8. Only adults aged 18-55 years who received a single dose of Menactra® (Group 4b) or MenACYW Conjugate vaccine (Group 1b-3b) from any of the lots 1, 2 or 3, were included in this outcome measure.

    Time frame: Day 30 (post-vaccination)

  2. Percentage of Participants Achieving hSBA Vaccine Seroresponse for Meningococcal Serogroups A, C, Y And W Following Vaccination With Either MenACYW Conjugate Vaccine or Menactra® Vaccine in Adolescents

    Antibody titers against meningococcal serogroups A, C, Y, and W measured by hSBA. The hSBA vaccine seroresponse for serogroups A, C, Y, and W was defined as post-vaccination hSBA titers \>= 1:16 for participants with pre-vaccination hSBA titers \< 1:8 or at least a 4-fold increase in hSBA titers from pre- to post-vaccination for participants with pre-vaccination hSBA titers \>= 1:8. Only adolescents aged 10-17 years who received a single dose of Menactra® (Group 4a) or MenACYW Conjugate vaccine (Group 1a-3a) from any of the lots 1, 2 or 3, were included in this outcome measure.

    Time frame: Day 30 (post-vaccination)

  3. Percentage of Participants Achieving hSBA Vaccine Seroresponse for Meningococcal Serogroups A, C, Y And W Following Vaccination With 3 Lots of MenACYW Conjugate Vaccine

    Antibody titers against meningococcal serogroups A, C, Y, and W measured by hSBA. The hSBA vaccine seroresponse for serogroups A, C, Y, and W was defined as post-vaccination hSBA titers \>= 1:16 for participants with pre-vaccination hSBA titers \< 1:8 or at least a 4-fold increase in hSBA titers from pre- to post-vaccination for participants with pre-vaccination hSBA titers \>= 1:8.

    Time frame: Day 30 (post-vaccination)

  4. Geometric Mean Titers (GMTs) of Meningococcal Serogroups A, C, Y, and W Antibodies Following Vaccination With MenACYW Conjugate and Menactra®

    Antibody titers of meningococcal serogroups A, C, Y, and W were measured by hSBA.

    Time frame: Day 30 (post-vaccination)

08

Results

Posted Mar 9, 2020

Participant flow

Study participants were enrolled in 90 centers in the United States (US) from 15 July 2016 to 16 August 2016.

Participant flow — Overall Study
MilestoneMenACYW Conjugate Vaccine Lot 1MenACYW Conjugate Vaccine Lot 2MenACYW Conjugate Vaccine Lot 3Menactra®
Started902895906641
Vaccinated895886900636
Safety analysis set (safas)895883898635
Completed879861885617
Not completed23342124
Withdrew: Non-compliance with the protocol3725
Withdrew: Subject met exclusion criteria0100
Withdrew: Withdrawal by subject111398
Withdrew: Lost to follow-up9131011

Outcome measures

PrimaryGeometric Mean Titers (GMTs) of Meningococcal Serogroups A, C, Y, And W Antibodies Following Vaccination With 3 Lots of MenACYW Conjugate Vaccine

Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by serum bactericidal assay using human complement (hSBA). Data for this outcome measure were not planned to be collected and analyzed for the Menactra® reporting group.

Time frame:
Day 30 (post-vaccination)
Reported as:
Geometric mean · Titer (1/dilution)
Geometric Mean Titers (GMTs) of Meningococcal Serogroups A, C, Y, And W Antibodies Following Vaccination With 3 Lots of MenACYW Conjugate Vaccine
Titer (1/dilution)MenACYW Conjugate Vaccine Lot 1MenACYW Conjugate Vaccine Lot 2MenACYW Conjugate Vaccine Lot 3
Serogroup A84.9 (75.8 to 95.1)96.5 (86.4 to 108)97.9 (87.7 to 109)
Serogroup C326 (286 to 372)305 (267 to 349)352 (307 to 405)
Serogroup Y213 (191 to 238)210 (188 to 234)218 (194 to 246)
Serogroup W84.5 (75.1 to 95.1)81.6 (72.7 to 91.5)87.2 (77.2 to 98.5)
Statistical analysis
  • MenACYW Conjugate Vaccine Lot 1 vs MenACYW Conjugate Vaccine Lot 2 · Gmt ratio: 0.880 · 95% CI 0.751 to 1.03
  • MenACYW Conjugate Vaccine Lot 2 vs MenACYW Conjugate Vaccine Lot 3 · Gmt ratio: 0.985 · 95% CI 0.843 to 1.15
  • MenACYW Conjugate Vaccine Lot 1 vs MenACYW Conjugate Vaccine Lot 3 · Gmt ratio: 0.867 · 95% CI 0.740 to 1.02
  • MenACYW Conjugate Vaccine Lot 1 vs MenACYW Conjugate Vaccine Lot 2 · Gmt ratio: 1.07 · 95% CI 0.888 to 1.29
  • MenACYW Conjugate Vaccine Lot 2 vs MenACYW Conjugate Vaccine Lot 3 · Gmt ratio: 0.866 · 95% CI 0.714 to 1.05
  • MenACYW Conjugate Vaccine Lot 1 vs MenACYW Conjugate Vaccine Lot 3 · Gmt ratio: 0.927 · 95% CI 0.766 to 1.12
  • MenACYW Conjugate Vaccine Lot 1 vs MenACYW Conjugate Vaccine Lot 2 · Gmt ratio: 1.02 · 95% CI 0.869 to 1.19
  • MenACYW Conjugate Vaccine Lot 2 vs MenACYW Conjugate Vaccine Lot 3 · Gmt ratio: 0.961 · 95% CI 0.816 to 1.13
  • MenACYW Conjugate Vaccine Lot 1 vs MenACYW Conjugate Vaccine Lot 3 · Gmt ratio: 0.975 · 95% CI 0.829 to 1.15
  • MenACYW Conjugate Vaccine Lot 1 vs MenACYW Conjugate Vaccine Lot 2 · Gmt ratio: 1.04 · 95% CI 0.878 to 1.22
  • MenACYW Conjugate Vaccine Lot 2 vs MenACYW Conjugate Vaccine Lot 3 · Gmt ratio: 0.936 · 95% CI 0.791 to 1.11
  • MenACYW Conjugate Vaccine Lot 1 vs MenACYW Conjugate Vaccine Lot 3 · Gmt ratio: 0.970 · 95% CI 0.818 to 1.15
PrimaryPercentage of Participants Achieving hSBA Vaccine Seroresponse for Meningococcal Serogroups A, C, Y And W Following Vaccination With Either MenACYW Conjugate Vaccine or Menactra® Vaccine

Antibody titers against meningococcal serogroups A, C, Y, and W measured by hSBA. The hSBA vaccine seroresponse for serogroups A, C, Y, and W was defined as post-vaccination hSBA titers \>= 1:16 for participants with pre-vaccination hSBA titers \< 1:8 or at least a 4-fold increase in hSBA titers from pre- to post-vaccination for participants with pre-vaccination hSBA titers \>= 1:8.

Time frame:
Day 30 (post-vaccination)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving hSBA Vaccine Seroresponse for Meningococcal Serogroups A, C, Y And W Following Vaccination With Either MenACYW Conjugate Vaccine or Menactra® Vaccine
percentage of participantsMenACYW Conjugate Vaccine (Groups 1, 2, 3 Pooled)Menactra®
Serogroup A73.8 (72.0 to 75.5)54.6 (50.5 to 58.7)
Serogroup C88.8 (87.5 to 90.0)47.9 (43.8 to 52.0)
Serogroup Y91.4 (90.3 to 92.5)73.4 (69.6 to 76.9)
Serogroup W80.3 (78.7 to 81.8)61.2 (57.2 to 65.2)
Statistical analysis
  • MenACYW Conjugate Vaccine (Groups 1, 2, 3 Pooled) vs Menactra® · Percentage difference: 19.1 · 95% CI 14.8 to 23.5
  • MenACYW Conjugate Vaccine (Groups 1, 2, 3 Pooled) vs Menactra® · Percentage difference: 40.9 · 95% CI 36.7 to 45
  • MenACYW Conjugate Vaccine (Groups 1, 2, 3 Pooled) vs Menactra® · Percentage difference: 18.1 · 95% CI 14.5 to 21.9
  • MenACYW Conjugate Vaccine (Groups 1, 2, 3 Pooled) vs Menactra® · Percentage difference: 19.1 · 95% CI 14.9 to 23.3
SecondaryPercentage of Participants Achieving hSBA Vaccine Seroresponse for Meningococcal Serogroups A, C, Y And W Following Vaccination With Either MenACYW Conjugate Vaccine or Menactra® Vaccine in Adults

Antibody titers against meningococcal serogroups A, C, Y, and W measured by hSBA. The hSBA vaccine seroresponse for serogroups A, C, Y, and W was defined as post-vaccination hSBA titers \>= 1:16 for participants with pre-vaccination hSBA titers \< 1:8 or at least a 4-fold increase in hSBA titers from pre- to post-vaccination for participants with pre-vaccination hSBA titers \>= 1:8. Only adults aged 18-55 years who received a single dose of Menactra® (Group 4b) or MenACYW Conjugate vaccine (Group 1b-3b) from any of the lots 1, 2 or 3, were included in this outcome measure.

Time frame:
Day 30 (post-vaccination)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving hSBA Vaccine Seroresponse for Meningococcal Serogroups A, C, Y And W Following Vaccination With Either MenACYW Conjugate Vaccine or Menactra® Vaccine in Adults
percentage of participantsMenACYW Conjugate Vaccine (Groups 1, 2, 3 Pooled)Menactra®
Serogroup A73.5 (71.2 to 75.8)53.9 (48.0 to 59.7)
Serogroup C83.4 (81.4 to 85.3)42.3 (36.6 to 48.2)
Serogroup Y88.1 (86.3 to 89.8)60.8 (54.9 to 66.4)
Serogroup W77.0 (74.7 to 79.2)50.2 (44.3 to 56.0)
Statistical analysis
  • MenACYW Conjugate Vaccine (Groups 1, 2, 3 Pooled) vs Menactra® · Percentage difference: 19.6 · 95% CI 13.5 to 25.8
  • MenACYW Conjugate Vaccine (Groups 1, 2, 3 Pooled) vs Menactra® · Percentage difference: 41.1 · 95% CI 35.0 to 46.9
  • MenACYW Conjugate Vaccine (Groups 1, 2, 3 Pooled) vs Menactra® · Percentage difference: 27.4 · 95% CI 21.7 to 33.3
  • MenACYW Conjugate Vaccine (Groups 1, 2, 3 Pooled) vs Menactra® · Percentage difference: 26.8 · 95% CI 20.7 to 32.9
SecondaryPercentage of Participants Achieving hSBA Vaccine Seroresponse for Meningococcal Serogroups A, C, Y And W Following Vaccination With Either MenACYW Conjugate Vaccine or Menactra® Vaccine in Adolescents

Antibody titers against meningococcal serogroups A, C, Y, and W measured by hSBA. The hSBA vaccine seroresponse for serogroups A, C, Y, and W was defined as post-vaccination hSBA titers \>= 1:16 for participants with pre-vaccination hSBA titers \< 1:8 or at least a 4-fold increase in hSBA titers from pre- to post-vaccination for participants with pre-vaccination hSBA titers \>= 1:8. Only adolescents aged 10-17 years who received a single dose of Menactra® (Group 4a) or MenACYW Conjugate vaccine (Group 1a-3a) from any of the lots 1, 2 or 3, were included in this outcome measure.

Time frame:
Day 30 (post-vaccination)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving hSBA Vaccine Seroresponse for Meningococcal Serogroups A, C, Y And W Following Vaccination With Either MenACYW Conjugate Vaccine or Menactra® Vaccine in Adolescents
percentage of participantsMenACYW Conjugate Vaccine (Groups 1, 2, 3 Pooled)Menactra®
Serogroup A74.0 (71.3 to 76.6)55.3 (49.5 to 61.0)
Serogroup C95.6 (94.2 to 96.8)53.3 (47.5 to 59.1)
Serogroup Y95.6 (94.2 to 96.8)85.7 (81.2 to 89.4)
Serogroup W84.5 (82.2 to 86.6)72.0 (66.6 to 77.0)
Statistical analysis
  • MenACYW Conjugate Vaccine (Groups 1, 2, 3 Pooled) vs Menactra® · Percentage difference: 18.7 · 95% CI 12.5 to 24.9
  • MenACYW Conjugate Vaccine (Groups 1, 2, 3 Pooled) vs Menactra® · Percentage difference: 42.3 · 95% CI 36.6 to 48.0
  • MenACYW Conjugate Vaccine (Groups 1, 2, 3 Pooled) vs Menactra® · Percentage difference: 10.0 · 95% CI 6.18 to 14.5
  • MenACYW Conjugate Vaccine (Groups 1, 2, 3 Pooled) vs Menactra® · Percentage difference: 12.5 · 95% CI 7.22 to 18.2
SecondaryPercentage of Participants Achieving hSBA Vaccine Seroresponse for Meningococcal Serogroups A, C, Y And W Following Vaccination With 3 Lots of MenACYW Conjugate Vaccine

Antibody titers against meningococcal serogroups A, C, Y, and W measured by hSBA. The hSBA vaccine seroresponse for serogroups A, C, Y, and W was defined as post-vaccination hSBA titers \>= 1:16 for participants with pre-vaccination hSBA titers \< 1:8 or at least a 4-fold increase in hSBA titers from pre- to post-vaccination for participants with pre-vaccination hSBA titers \>= 1:8.

Time frame:
Day 30 (post-vaccination)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving hSBA Vaccine Seroresponse for Meningococcal Serogroups A, C, Y And W Following Vaccination With 3 Lots of MenACYW Conjugate Vaccine
percentage of participantsMenACYW Conjugate Vaccine Lot 1MenACYW Conjugate Vaccine Lot 2MenACYW Conjugate Vaccine Lot 3
Serogroup A71.1 (67.9 to 74.2)76.5 (73.5 to 79.4)73.7 (70.6 to 76.6)
Serogroup C90.5 (88.3 to 92.4)89.1 (86.8 to 91.2)86.7 (84.3 to 88.9)
Serogroup Y92.4 (90.4 to 94.1)91.9 (89.9 to 93.7)89.9 (87.7 to 91.9)
Serogroup W81.5 (78.7 to 84.0)80.7 (77.8 to 83.4)78.7 (75.8 to 81.4)
Statistical analysis
  • MenACYW Conjugate Vaccine Lot 1 vs MenACYW Conjugate Vaccine Lot 2 · Percentage difference: -5.4 · 95% CI -9.59 to -1.16
  • MenACYW Conjugate Vaccine Lot 2 vs MenACYW Conjugate Vaccine Lot 3 · Percentage difference: 2.9 · 95% CI -1.3 to 7.01
  • MenACYW Conjugate Vaccine Lot 1 vs MenACYW Conjugate Vaccine Lot 3 · Percentage difference: -2.5 · 95% CI -6.78 to 1.74
  • MenACYW Conjugate Vaccine Lot 1 vs MenACYW Conjugate Vaccine Lot 2 · Percentage difference: 1.3 · 95% CI -1.58 to 4.28
  • MenACYW Conjugate Vaccine Lot 2 vs MenACYW Conjugate Vaccine Lot 3 · Percentage difference: 2.4 · 95% CI -0.740 to 5.54
  • MenACYW Conjugate Vaccine Lot 1 vs MenACYW Conjugate Vaccine Lot 3 · Percentage difference: 3.7 · 95% CI 0.708 to 6.79
  • MenACYW Conjugate Vaccine Lot 1 vs MenACYW Conjugate Vaccine Lot 2 · Percentage difference: 0.5 · 95% CI -2.14 to 3.07
  • MenACYW Conjugate Vaccine Lot 2 vs MenACYW Conjugate Vaccine Lot 3 · Percentage difference: 2.0 · 95% CI -0.763 to 4.79
  • MenACYW Conjugate Vaccine Lot 1 vs MenACYW Conjugate Vaccine Lot 3 · Percentage difference: 2.5 · 95% CI -0.248 to 5.20
  • MenACYW Conjugate Vaccine Lot 1 vs MenACYW Conjugate Vaccine Lot 2 · Percentage difference: 0.8 · 95% CI -3.00 to 4.54
  • MenACYW Conjugate Vaccine Lot 2 vs MenACYW Conjugate Vaccine Lot 3 · Percentage difference: 2.0 · 95% CI -1.84 to 5.89
  • MenACYW Conjugate Vaccine Lot 1 vs MenACYW Conjugate Vaccine Lot 3 · Percentage difference: 2.8 · 95% CI -1.02 to 6.61
SecondaryGeometric Mean Titers (GMTs) of Meningococcal Serogroups A, C, Y, and W Antibodies Following Vaccination With MenACYW Conjugate and Menactra®

Antibody titers of meningococcal serogroups A, C, Y, and W were measured by hSBA.

Time frame:
Day 30 (post-vaccination)
Reported as:
Geometric mean · Titer (1/dilution)
Geometric Mean Titers (GMTs) of Meningococcal Serogroups A, C, Y, and W Antibodies Following Vaccination With MenACYW Conjugate and Menactra®
Titer (1/dilution)MenACYW Conjugate Vaccine (Groups 1, 2, 3 Pooled)Menactra®
Serogroup A92.9 (87.1 to 99.1)48.1 (41.8 to 55.2)
Serogroup C328 (303 to 354)40.7 (33.8 to 49.0)
Serogroup Y214 (200 to 228)66.4 (56.4 to 78.0)
Serogroup W84.4 (78.8 to 90.4)44.5 (38.3 to 51.7)
Statistical analysis
  • MenACYW Conjugate Vaccine (Groups 1, 2, 3 Pooled) vs Menactra® · Gmt ratio: 1.93 · 95% CI 1.67 to 2.24
  • MenACYW Conjugate Vaccine (Groups 1, 2, 3 Pooled) vs Menactra® · Gmt ratio: 8.05 · 95% CI 6.58 to 9.84
  • MenACYW Conjugate Vaccine (Groups 1, 2, 3 Pooled) vs Menactra® · Gmt ratio: 3.22 · 95% CI 2.71 to 3.84
  • MenACYW Conjugate Vaccine (Groups 1, 2, 3 Pooled) vs Menactra® · Gmt ratio: 1.90 · 95% CI 1.61 to 2.24

Adverse events

Collected over Adverse event (AE) data were collected from Day 0 (post-vaccination) up to 30 days after vaccination. Solicited reaction (SR) data were collected within 7 days after vaccination. Serious adverse event (SAE) data were collected throughout the study (up to 180 days after vaccination).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MenACYW Conjugate Vaccine Lot 10/895 (0%)9/895 (1%)477/895 (53.3%)
MenACYW Conjugate Vaccine Lot 20/883 (0%)13/883 (1.5%)485/883 (54.9%)
MenACYW Conjugate Vaccine Lot 30/898 (0%)6/898 (0.7%)489/898 (54.5%)
Menactra0/635 (0%)5/635 (0.8%)353/635 (55.6%)
Most frequent serious events
Showing 10 of 35
Most frequent serious events
EventMenACYW Conjugate Vaccine Lot 1MenACYW Conjugate Vaccine Lot 2MenACYW Conjugate Vaccine Lot 3Menactra
AppendicitisInfections and infestations1/8952/8830/8980/635
Gastroenteritis norovirusInfections and infestations0/8950/8830/8981/635
Diabetes mellitus inadequate controlMetabolism and nutrition disorders0/8950/8830/8981/635
Disruptive mood dysregulation disorderPsychiatric disorders0/8950/8830/8981/635
NephrolithiasisRenal and urinary disorders0/8950/8830/8981/635
Throat tightnessRespiratory, thoracic and mediastinal disorders0/8950/8830/8981/635
Henoch-Schonlein purpuraSkin and subcutaneous tissue disorders0/8950/8830/8981/635
Coronary artery diseaseCardiac disorders0/8951/8830/8980/635
Chest painGeneral disorders1/8951/8830/8980/635
Appendicitis perforatedInfections and infestations0/8951/8830/8980/635
Most frequent other events
Most frequent other events
EventMenACYW Conjugate Vaccine Lot 1MenACYW Conjugate Vaccine Lot 2MenACYW Conjugate Vaccine Lot 3Menactra
Injection site painGeneral disorders344/895339/883333/898235/635
MyalgiaMusculoskeletal and connective tissue disorders278/895271/883294/898192/635
HeadacheNervous system disorders247/895248/883253/898175/635
MalaiseGeneral disorders184/895186/883189/898132/635
Injection site erythemaGeneral disorders45/89539/88343/89825/635

Baseline characteristics

Analysis was performed on all randomized participants.

Age, Categorical
Age, Categorical(Participants)MenACYW Conjugate Vaccine Lot 1MenACYW Conjugate Vaccine Lot 2MenACYW Conjugate Vaccine Lot 3Menactra®Total
<=18 years4024003973291528
Between 18 and 65 years5004955093121816
>=65 years00000
Age, Continuous
Age, Continuous(years)MenACYW Conjugate Vaccine Lot 1MenACYW Conjugate Vaccine Lot 2MenACYW Conjugate Vaccine Lot 3Menactra®Total
Mean27.4 ± 15.627.1 ± 15.727.3 ± 15.525.6 ± 15.427.0 ± 15.6
Sex: Female, Male
Sex: Female, Male(Participants)MenACYW Conjugate Vaccine Lot 1MenACYW Conjugate Vaccine Lot 2MenACYW Conjugate Vaccine Lot 3Menactra®Total
Female5355314963571919
Male3673644102841425
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MenACYW Conjugate Vaccine Lot 1MenACYW Conjugate Vaccine Lot 2MenACYW Conjugate Vaccine Lot 3Menactra®Total
Hispanic or Latino191207188141727
Not Hispanic or Latino7106857165002611
Unknown or Not Reported13206
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MenACYW Conjugate Vaccine Lot 1MenACYW Conjugate Vaccine Lot 2MenACYW Conjugate Vaccine Lot 3Menactra®Total
American Indian or Alaska Native175316
Asian919191461
Native Hawaiian or Other Pacific Islander643215
Black or African American175186166121648
White6806476834782488
More than one race30293021110
Unknown or Not Reported13026
Region of Enrollment
Region of Enrollment(Participants)MenACYW Conjugate Vaccine Lot 1MenACYW Conjugate Vaccine Lot 2MenACYW Conjugate Vaccine Lot 3Menactra®Total
United States9028959066413344
09

Study locations

89 sites
  • Birmingham, Alabama 35205, United States
  • Dothan, Alabama 36305, United States
  • Mobile, Alabama 36608, United States
  • Glendale, Arizona 85308, United States
  • Mesa, Arizona 85213, United States
  • Phoenix, Arizona 85018, United States
  • Harrisburg, Arkansas 72432, United States
  • Jonesboro, Arkansas 72401, United States
  • Anaheim, California 92804, United States
  • Downey, California 90241, United States
  • Los Angeles, California 90057, United States
  • Paramount, California 90723, United States
  • Redding, California 96001, United States
  • Sacramento, California 95825, United States
  • San Diego, California 92102, United States
  • San Diego, California 92103, United States
  • San Diego, California 96001, United States
  • Santa Rosa, California 95405, United States
  • Upland, California 91786, United States
  • West Covina, California 91790, United States
  • Littleton, Colorado 80128, United States
  • DeLand, Florida 32720, United States
  • Hialeah, Florida 33012, United States
  • Hialeah, Florida 33016, United States
  • Miami, Florida 33142, United States
  • Orlando, Florida 32806, United States
  • Saint Petersburg, Florida 33710, United States
  • Sarasota, Florida 34239, United States
  • South Miami, Florida 33143, United States
  • West Palm Beach, Florida 33409, United States
  • Savannah, Georgia 31406, United States
  • Meridian, Idaho 83642, United States
  • Council Bluffs, Iowa 51503, United States
  • Lenexa, Kansas 66219, United States
  • Newton, Kansas 67114, United States
  • Park City, Kansas 67219, United States
  • Wichita, Kansas 67205, United States
  • Wichita, Kansas 67207, United States
  • Bardstown, Kentucky 40004, United States
  • Metairie, Louisiana 70006, United States
  • Bridgeton, Missouri 63044, United States
  • Kansas City, Missouri 64114, United States
  • Saint Louis, Missouri 63141, United States
  • Lincoln, Nebraska 60505, United States
  • Lincoln, Nebraska 68522, United States
  • Omaha, Nebraska 68114, United States
  • Omaha, Nebraska 68134, United States
  • Charlotte, North Carolina 28209, United States
  • Raleigh, North Carolina 27609, United States
  • Raleigh, North Carolina 27612, United States
  • Salisbury, North Carolina 28144, United States
  • Fargo, North Dakota 58104, United States
  • Cincinnati, Ohio 45245, United States
  • Cincinnati, Ohio 45246, United States
  • Cleveland, Ohio 44122, United States
  • Dayton, Ohio 45414, United States
  • Dayton, Ohio 45419, United States
  • Corvallis, Oregon 97330, United States
  • Grants Pass, Oregon 97527, United States
  • Erie, Pennsylvania 16505, United States
  • Hermitage, Pennsylvania 16148, United States
  • McMurray, Pennsylvania 15317, United States
  • Upper Saint Clair, Pennsylvania 15241, United States
  • Warwick, Rhode Island 02886, United States
  • Charleston, South Carolina 29407, United States
  • Charleston, South Carolina 29414, United States
  • Mount Pleasant, South Carolina 29464, United States
  • Jackson, Tennessee 38305, United States
  • Nashville, Tennessee 37203, United States
  • Tullahoma, Tennessee 37388, United States
  • Corpus Christi, Texas 78413, United States
  • Fort Worth, Texas 76104, United States
  • Fort Worth, Texas 76107, United States
  • San Antonio, Texas 78229, United States
  • Waxahachie, Texas 75165, United States
  • Draper, Utah 84020, United States
  • Layton, Utah 84041, United States
  • Murray, Utah 84123, United States
  • Orem, Utah 84058, United States
  • Salt Lake City, Utah 84109, United States
  • Salt Lake City, Utah 84121, United States
  • South Jordan, Utah 84095, United States
  • West Jordan, Utah 83642, United States
  • West Jordan, Utah 84088, United States
  • Burke, Virginia 22015, United States
  • Charlottesville, Virginia 22911, United States
  • Charlottesville, Virginia 29902, United States
  • Midlothian, Virginia 23113, United States
  • Richmond, Virginia 23294, United States
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2016 to primary completion in Feb 2017, 7 months.

Results were first posted in Mar 2020, 3 years after primary completion. A results delay was requested in Feb 2018.

Of 25 phase 3 interventional studies under Meningitis, Meningococcal, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 20. This study's 7 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2016
First posted
Jul 25, 2016
StartActual
Jul 15, 2016
Primary completionActual
Feb 28, 2017
CompletionActual
Feb 28, 2017
Results delay requested
Feb 26, 2018
Results first posted
Mar 9, 2020
Last update
Apr 5, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02842853
Responsible party
Sponsor
First posted
Jul 25, 2016
Start date
Jul 15, 2016
Primary completion
Feb 28, 2017
Completion
Feb 28, 2017
Results posted
Mar 9, 2020
Last update
Apr 5, 2022

Study contacts

Medical Director
study director · Sanofi Pasteur Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion